Korean biopharmaceutical giant ships biosimilar to US
South Korean biopharmaceutical powerhouse Celltrion announced on Feb. 28 that it had shipped the first batch of its new autoimmune disease treatment Zymfentra to the United States.
The treatment, otherwise known as Remsima SC, is set to debut in the United States next month.
As a subcutaneous injection version of Remsima, the infliximab biosimilar of Celltrion, Zymfentra won the approval of the U.S. Food and Drug Administration.
Recognizing its therapeutic effectiveness, more than 50 countries, including those in Europe and Canada, have authorized Remsima SC, which chalked up success there.
Based on the positive track record, Celltrion strives to bring Remsima SC to the lucrative U.S. market, which is estimated to be bigger than $10 billion.
In particular, Celltrion is scheduled to focus on inflammatory bowel disease.
Celltrion expects that the first batch bounded for Atlanta will be available in the U.S. market midway through next month.